Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Serotype 2α1-Antitrypsin (AAT) Vector in AAT-Deficient Adults
- 1 December 2006
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 17 (12), 1177-1186
- https://doi.org/10.1089/hum.2006.17.1177
Abstract
A phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 (rAAV2) α1- antitrypsin (AAT) vector was performed in 12 AAT-deficient adults, 10 of whom were male. All subjects were either homozygous for the most common AAT mutation (a missense mutation designated PI*Z) or compound heterozygous for PI*Z and another mutation known to cause disease. There were four dose cohorts, ranging from 2.1 × 1012 vector genomes (VG) to 6.9 × 1013 VG, with three subjects per cohort. Subjects were injected sequentially in a dose-escalating fashion with a minimum of 14 days between patients. Subjects who had been receiving AAT protein replacement discontinued that therapy 28 days before vector administration. There were no vector-related serious adverse events in any of the 12 participants. Vector DNA sequences were detected in the blood between 1 and 3 days after injection in nearly all patients receiving doses of 6.9 × 1012 VG or higher. Anti-AAV2 capsid antibodies were present and rose after vector injection, but no other immune responses were detected. One subject who had not been receiving protein replacement exhibited low-level expression of wild-type M-AAT in the serum (82 nM), which was detectable 30 days after receiving an injection of 2.1 × 1013 VG. Unfortunately, residual but declining M-AAT levels from the washout of the protein replacement elevated background levels sufficiently to obscure any possible vector expression in that range in most of the other individuals in the higher dose cohorts.Keywords
This publication has 44 references indexed in Scilit:
- Efficient Hepatic Delivery and Expression from a Recombinant Adeno-associated Virus 8 Pseudotyped α1-Antitrypsin VectorMolecular Therapy, 2005
- Major role of local immune responses in antibody formation to factor IX in AAV gene transferGene Therapy, 2005
- Workshop on Long-term Follow-up of Participants in Human Gene Transfer ResearchMolecular Therapy, 2004
- Gene transfer into skeletal muscle using novel AAV serotypesThe Journal of Gene Medicine, 2004
- Erythropoietin gene therapy leads to autoimmune anemia in macaquesBlood, 2004
- Influence of Vector Dose on Factor IX-Specific T and B Cell Responses in Muscle-Directed Gene TherapyHuman Gene Therapy, 2002
- Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectorsGene Therapy, 2001
- CMV-β-Actin Promoter Directs Higher Expression from an Adeno-Associated Viral Vector in the Liver than the Cytomegalovirus or Elongation Factor 1α Promoter and Results in Therapeutic Levels of Human Factor X in MiceHuman Gene Therapy, 2001
- Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primatesGene Therapy, 1998
- Replacement Therapy for Alpha1-Antitrypsin Deficiency Associated with EmphysemaNew England Journal of Medicine, 1987